Waycross Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waycross Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,000	Closed	-$619K	–	84
2023 Q3	$619K	Hold	7,000	–	–	0.14%	71
2023 Q2	$607K	Hold	7,000	–	–	0.13%	76
2023 Q1	$681K	Hold	7,000	–	–	0.2%	64
2022 Q4	$724K	Buy	7,000 +600	+9%	+$56.3K	0.26%	58
2022 Q3	$543K	Hold	6,400	–	–	0.37%	68
2022 Q2	$530K	Hold	6,400	–	–	0.35%	67
2022 Q1	$493K	Hold	6,400	–	–	0.29%	72
2021 Q4	$565K	Buy	6,400 +1,800	+39%	+$149K	0.32%	72
2021 Q3	$356K	Hold	4,600	–	–	0.22%	83
2021 Q2	$384K	Hold	4,600	–	–	0.2%	71
2021 Q1	$347K	Hold	4,600	–	–	0.19%	79
2020 Q4	$403K	Buy	+4,600	New	+$365K	0.25%	72

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Waycross Partners's BMRN Position: Q4 2023 in Review

Waycross Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 7,000 shares — an estimated $619K sold.

Waycross Partners first reported a position in BMRN in Q4 2020 and held it in 12 quarters. The position peaked at $724K in Q4 2022. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Waycross Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Waycross Partners sold 7,000 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $619K.
Waycross Partners first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Waycross Partners's BioMarin Pharmaceuticals position peaked at $724K in Q4 2022.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Waycross Partners's 13F filing for Q4 2023, filed 5 Feb 2024.